Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc. Share Price (NASDAQ: DCPH)

▲

-25.59

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 10 Jun 2024

Check the interactive Deciphera Pharmaceuticals, Inc. Stock chart to analyse performance

Deciphera Pharmaceuticals, Inc. Key Stats

Check Deciphera Pharmaceuticals, Inc. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$25.59
Open
$25.56
Market Capitalization
$2.2B
Today's Volume
$1.6M
Revenue TTM
$174.9M
EBITDA
$-204.6M
Earnings Per Share (EPS)
$-2.21
Profit Margin
-108.87%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-50.37%

Global Institutional Holdings in Deciphera Pharmaceuticals, Inc.

  • Name

    Holdings %

  • BlackRock Inc

    6.93%

  • Armistice Capital, LLC

    6.82%

  • Redmile Group, LLC

    6.13%

  • Deerfield Management Co

    5.93%

  • Vanguard Group Inc

    5.28%

  • State Street Corporation

    3.58%

Analyst Recommendation on Deciphera Pharmaceuticals, Inc. Stock

Rating
Trend

Buy

    50%Buy

    50%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Deciphera Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)

About Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Organization
Deciphera Pharmaceuticals, Inc.
Employees
355
CEO
Mr. Steven L. Hoerter
Industry
Health Technology

Important FAQs about investing in DCPH Stock from India :

What is Deciphera Pharmaceuticals, Inc. share price today?

Deciphera Pharmaceuticals, Inc. share price today is as on at the close of the market. Deciphera Pharmaceuticals, Inc. share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Deciphera Pharmaceuticals, Inc. share?

Deciphera Pharmaceuticals, Inc. share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Deciphera Pharmaceuticals, Inc. stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Deciphera Pharmaceuticals, Inc. Stock (DCPH) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Deciphera Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Deciphera Pharmaceuticals, Inc. Shares .

What is the minimum amount required to buy Deciphera Pharmaceuticals, Inc. Stock (DCPH) from India?

Indian investors can start investing in Deciphera Pharmaceuticals, Inc. (DCPH) shares with as little as ₹88.3 or $1 (as of September 14, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹883.00 in Deciphera Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on September 14, 2025). Learn more about fractional shares .

What are the returns that Deciphera Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?

Deciphera Pharmaceuticals, Inc. stock has given 0.0% share price returns and 20.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?